Lipocine Inc. (LPCN)
Largest Insider Buys in Sector
LPCN Stock Price History Chart
LPCN Stock Performance
About Lipocine Inc.
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
Insider Activity of Lipocine Inc.
Over the last 12 months, insiders at Lipocine Inc. have bought $0 and sold $0 worth of Lipocine Inc. stock.
On average, over the past 5 years, insiders at Lipocine Inc. have bought $130,754 and sold $80,381 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,706 shares for transaction amount of $43,791 was made by Patel Mahesh V. (CEO and President) on 2023‑05‑25.
List of Insider Buy and Sell Transactions, Lipocine Inc.
| 2023-05-25 | Patel Mahesh V. | CEO and President | 8,706 0.1614% | $5.03 | $43,791 | -23.22% | ||
| 2023-03-24 | Patel Mahesh V. | CEO and President | 150,000 0.0107% | $0.32 | $48,000 | -21.17% | ||
| 2023-03-20 | Ono Richard Dana | director | 4,000 0.0003% | $0.34 | $1,360 | -27.78% | ||
| 2023-03-17 | Patel Mahesh V. | CEO and President | 50,000 0.0032% | $0.33 | $16,500 | -32.72% | ||
| 2022-11-22 | Papapetropoulos Spyros | director | 21,739 0.0015% | $0.47 | $10,217 | -37.34% | ||
| 2022-11-14 | Patel Mahesh V. | CEO and President | 75,000 0.0051% | $0.39 | $29,250 | -23.30% | ||
| 2022-09-27 | Patel Mahesh V. | CEO and President | 100,000 0.0069% | $0.41 | $41,000 | -19.01% | ||
| 2022-05-17 | Fogarty Krista | Principal Accounting Officer | 12,500 0.0008% | $0.86 | $10,750 | -48.86% | ||
| 2022-05-16 | Patel Mahesh V. | CEO and President | 50,000 0.0032% | $0.77 | $38,495 | -39.62% | ||
| 2021-11-18 | Patel Mahesh V. | CEO and President | 25,000 0.0017% | $1.09 | $27,250 | -21.10% | ||
| 2020-12-31 | Sale | Higuchi John W. | director | 6,700 0.0005% | $1.35 | $9,054 | -0.74% | |
| 2020-12-16 | Sale | Patel Mahesh V. | Chief Executive Officer | 15,000 0.0013% | $1.35 | $20,250 | -1.45% | |
| 2020-12-16 | Sale | BROWN MORGAN R | EVP and CFO | 8,437 0.0007% | $1.35 | $11,390 | -1.45% | |
| 2020-12-04 | Sale | Patel Mahesh V. | Chief Executive Officer | 43,500 0.004% | $1.57 | $68,134 | -11.04% | |
| 2020-12-04 | Sale | BROWN MORGAN R | Chief Financial Officer | 17,250 0.0016% | $1.57 | $27,024 | -11.04% | |
| 2020-03-17 | Higuchi John W. | director | 220,000 0.0309% | $0.32 | $69,542 | +337.50% | ||
| 2019-12-31 | Patel Mahesh V. | CEO and President | 40,000 0.0057% | $0.38 | $15,340 | +214.29% | ||
| 2019-12-10 | Patel Mahesh V. | President and CEO | 25,000 0.0036% | $0.40 | $9,975 | +143.65% | ||
| 2019-12-04 | Sale | Patel Mahesh V. | CEO and President | 43,500 0.0061% | $0.41 | $17,835 | +123.97% | |
| 2019-12-04 | Sale | BROWN MORGAN R | EVP and Chief Financial Office | 17,250 0.0024% | $0.41 | $7,076 | +123.97% |
Insider Historical Profitability
| Higuchi John W. | director | 693548 13.0468% | $7.85 | 2 | 1 | +337.5% |
| BROWN MORGAN R | EVP and CFO | 194504 3.659% | $7.85 | 0 | 4 | |
| Patel Mahesh V. | CEO and President | 107418 2.0207% | $7.85 | 16 | 4 | +40.05% |
| Papapetropoulos Spyros | director | 21739 0.4089% | $7.85 | 1 | 0 | <0.0001% |
| Ono Richard Dana | director | 14125 0.2657% | $7.85 | 2 | 1 | +6.76% |
| Fogarty Krista | Principal Accounting Officer | 12500 0.2351% | $7.85 | 1 | 0 | <0.0001% |
| Bass Gregory Brooks | Chief Commercial Officer | 5625 0.1058% | $7.85 | 0 | 1 | |
| HILL STEPHEN A | director | 5250 0.0988% | $7.85 | 1 | 1 | +48.99% |
| Fink Jeffrey Arvin | director | 937 0.0176% | $7.85 | 0 | 1 |
Institutional Investor Ownership
| The Vanguard Group | $1.15M | 4.14 | 221,459 | 0% | +$0 | <0.0001 | |
| BlackRock | $387,514.00 | 1.39 | 74,522 | -0.43% | -$1,684.80 | <0.0001 | |
| Susquehanna International Group | $310,268.00 | 1.12 | 59,667 | +5.42% | +$15,943.18 | <0.0001 | |
| Geode Capital Management | $254,085.00 | 0.91 | 48,854 | 0% | +$0 | <0.0001 | |
| Two Sigma Advisers LP | $133,754.00 | 0.48 | 25,722 | -1.91% | -$2,599.99 | <0.0001 | |
| Renaissance Technologies | $110,000.00 | 0.39 | 21,097 | +12.24% | +$11,992.23 | <0.0001 | |
| State Street | $96,855.00 | 0.35 | 18,626 | 0% | +$0 | <0.0001 | |
| Tower Research Capital | $10,473.00 | 0.04 | 2,014 | -10.01% | -$1,164.82 | <0.0001 | |
| Morgan Stanley | $3,754.00 | 0.01 | 722 | 0% | +$0 | <0.0001 | |
| Caldwell Sutter Capital Inc | $2,449.00 | 0.01 | 471 | 0% | +$0 | <0.01 | |
| UBS | $2,241.00 | 0.01 | 431 | New | +$2,241.00 | <0.0001 | |
| Group One Trading | $208.00 | <0.01 | 40 | -23.08% | -$62.40 | <0.0001 | |
| Advisor Group Holdings Inc | $352.00 | <0.01 | 68 | 0% | +$0 | <0.0001 | |
| Wells Fargo | $218.00 | <0.01 | 42 | +2.44% | +$5.19 | <0.0001 | |
| Old Point Trust & Financial Service | $307.00 | <0.01 | 59 | New | +$307.00 | <0.0001 | |
| JPMorgan Chase | $62.00 | <0.01 | 12 | +33.33% | +$15.50 | <0.0001 | |
| Royal Bank of Canada | $0 | <0.01 | 14 | -84.61% | -$0 | <0.0001 |